Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

STAT-C: a full revolution or just a step forward?

Milazzo L, Antinori S.

Lancet. 2010 Aug 28;376(9742):662-3. doi: 10.1016/S0140-6736(10)61056-2. Epub 2010 Aug 6. No abstract available.

PMID:
20692692
2.

[Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].

Lange CM, Sarrazin C, Zeuzem S.

Pharm Unserer Zeit. 2011 Jan;40(1):60-7. doi: 10.1002/pauz.201100401. Review. German. No abstract available.

PMID:
21194084
3.

[Hepatitis C update: what has changed? What can we expect in the near future?].

Geier A.

MMW Fortschr Med. 2013 Nov 7;155(19):59-62. Review. German. No abstract available.

PMID:
24475674
4.

[New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].

Lennerstrand J, Bondeson K, Bergqvist A, Blomberg J, Oberg B.

Lakartidningen. 2009 Nov 25-Dec 1;106(48):3254-6, 3258, 3260. Review. Swedish. No abstract available.

PMID:
20101837
5.

Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.

Fernández-Yunquera A, Rincón D, Salcedo M, Bañares R.

Rev Esp Quimioter. 2013 Sep;26(3):189-92. Review. No abstract available.

6.

[Boceprevir (Victrelis), oral administration].

[No authors listed]

J Pharm Belg. 2012 Jun;(2):37-9. Review. French. No abstract available.

PMID:
22978014
7.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7. Review.

PMID:
22156853
8.
9.

Directly acting antivirals against hepatitis C virus.

Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P.

J Antimicrob Chemother. 2011 Aug;66(8):1673-86. doi: 10.1093/jac/dkr215. Epub 2011 Jun 7. Review.

PMID:
21652618
10.

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.

Seden K, Back D.

Curr Opin HIV AIDS. 2011 Nov;6(6):514-26. doi: 10.1097/COH.0b013e32834b54dc. Review.

PMID:
22001895
11.

[Telaprevir resistance].

Poveda E, García F.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Review. Spanish.

PMID:
24063900
12.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Welsch C, Jesudian A, Zeuzem S, Jacobson I.

Gut. 2012 May;61 Suppl 1:i36-46. doi: 10.1136/gutjnl-2012-302144. Review. Erratum in: Gut. 2012 Aug;61(8):1145.

PMID:
22504918
13.

[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].

Kozielewicz D, Halota W, Dybowska D.

Przegl Epidemiol. 2012;66(1):49-54. Review. Polish.

14.

Hepatitis C virus resistance to protease inhibitors.

Halfon P, Locarnini S.

J Hepatol. 2011 Jul;55(1):192-206. doi: 10.1016/j.jhep.2011.01.011. Epub 2011 Feb 1. Review.

15.

[Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].

Nikitin IG, Gogova LM, Baikova IE, Kislyakov VA, Volynkina VM.

Ter Arkh. 2012;84(11):75-80. Review. Russian.

PMID:
23252254
16.

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

Marks KM, Jacobson IM.

Antivir Ther. 2012;17(6 Pt B):1119-31. doi: 10.3851/IMP2424. Epub 2012 Oct 5. Review.

PMID:
23188750
17.

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).

Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board:.

Dig Liver Dis. 2014 Jan;46(1):18-24. doi: 10.1016/j.dld.2013.08.243. Epub 2013 Oct 9. Review.

18.

[Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].

Nikitin IG, Baĭkova IE, Gogova LM, Volynkina VM, Kisliakov VA.

Ter Arkh. 2013;85(2):76-84. Review. Russian.

PMID:
23653945
19.

The role of resistance in HCV treatment.

Vermehren J, Sarrazin C.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011. Review.

PMID:
23199507
20.

Management of the transplant recipient with chronic hepatitis C.

Burton JR Jr, Everson GT.

Clin Liver Dis. 2013 Feb;17(1):73-91. doi: 10.1016/j.cld.2012.09.013. Review.

PMID:
23177284

Supplemental Content

Support Center